Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer

Activated V 9V 2 T Cells Trigger Granulocyte Functions via MCP-2 Release

(2014) C. Agrati et al.   JOURNAL OF IMMUNOLOGY

Comparison of γδ T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid

(2013) Atif S. M. Idrees et al.   CANCER SCIENCE

Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain

(2013) Takamichi Izumi et al.   CYTOTHERAPY

Human γδ T-cell responses in infection and immunotherapy: Common mechanisms, common mediators?

(2012) Chiara Riganti et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Malignant ascites: pathophysiology and treatment

(2012) Emanuel Cavazzoni et al.   International Journal of Clinical Oncology

Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone

(2012) Jung Hun Kang et al.   JOURNAL OF CLINICAL ONCOLOGY

Cutting Edge: Nitrogen Bisphosphonate-Induced Inflammation Is Dependent upon Mast Cells and IL-1

(2012) J. T. Norton et al.   JOURNAL OF IMMUNOLOGY

Differentiation, phenotype, and function of interleukin-17-producing human V 9V 2 T cells

(2011) N. Caccamo et al.   BLOOD

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

(2011) Hirohito Kobayashi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote V 9V 2 T-Cell Chemotaxis and Cytotoxicity In Vivo

(2011) I. Benzaid et al.   CANCER RESEARCH

Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer

(2011) Haruhiko Imamoto et al.   Gastric Cancer

Japanese classification of gastric carcinoma: 3rd English edition

(2011)   Gastric Cancer

Adoptive Immunotherapy for Advanced Non-small CellLung Cancer Using Zoledronate-expanded γδTCells

(2011) Miki Sakamoto et al.   JOURNAL OF IMMUNOTHERAPY

Bisphosphonates' antitumor activity: An unravelled side of a multifaceted drug class

(2010) Philippe Clézardin   BONE

A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells☆☆☆

(2010) Jun Nakajima et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis

(2009) H. Ishigami et al.   ANNALS OF ONCOLOGY

Impact of culture medium on the expansion of T cells for immunotherapy

(2009) Keisuke Sato et al.   CYTOTHERAPY

Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP

(2008) Anke J. Roelofs et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*

(2008) M. Kondo et al.   CYTOTHERAPY

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY